Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...

Sanofi’s adoption of the Accumulus platform marks another move towards fit-for-purpose technology that ensures secure, real-time global regulatory connectivity. Many of the NRAs involved in the Sanofi ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Sanofi India Q3 Results Live : Sanofi India announced its Q3 results on November 7, 2024, revealing a significant decline in ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...